ARCUS BIOSCIENCES INC

RCUSNYSE

🏆 #1413 by market capEarnings Oct 27US Equity

$28.96▲ $0.22 (+0.77%)

Live

1h▲ 0.1%

24h▲ 0.8%

7d▲ 3.9%

14d▲ 9.5%

30d▲ 3.2%

1y▲ 199.2%

🏦Market Cap

$3.64B

Small Cap

📈Revenue Growth (YoY)

-50.0%

Declining

📊Gross Margin

—

💵FCF Margin

21.4%

Strong

⚖️P/S Ratio

31.4x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $28.83 – $29.11
52-Week Range: $8.88 – $31.74
Volume: $2.67B
Avg Volume: $2.75B
Shares Outstanding: 125.8M
Next Earnings: Sep 15, 2026

Fundamentals Snapshot

Annual Revenue: $247M
Last Q Revenue: $41M
P/E Ratio: —
P/S Ratio: 31.4x
EPS (TTM): $-3.90
Dividend Yield: —

Why Investors Own RCUS

✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
✓Healthy economics — 43% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$247M▲ +59.6% YoY

Gross Margin (TTM)

43.0%▲ +2.5% YoY

Operating Income (TTM)

$35M▲ +59.6% YoY

Free Cash Flow (TTM)

$34M▲ +59.6% YoY

About ARCUS BIOSCIENCES INC

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

🦦